ABSTRACT
Increased activation of the renin-angiotensin system is involved in the onset and progression of cardiometabolic diseases, while natriuretic peptides (NP) may exert protective effects. We have recently demonstrated that sacubitril/valsartan (LCZ696), a first-in-class angiotensin receptor neprilysin inhibitor, which blocks the angiotensin II type-1 receptor and augments natriuretic peptide levels, improved peripheral insulin sensitivity in obese hypertensive patients. Here, we investigated the effects of sacubitril/valsartan (400 mg QD) treatment for 8 weeks on the abdominal subcutaneous adipose tissue (AT) phenotype compared to the metabolically neutral comparator amlodipine (10 mg QD) in 70 obese hypertensive patients. Abdominal subcutaneous AT biopsies were collected before and after intervention to determine the AT transcriptome and expression of proteins involved in lipolysis, NP signaling and mitochondrial oxidative metabolism. Both sacubitril/valsartan and amlodipine treatment did not significantly induce AT transcriptional changes in pathways related to lipolysis, NP signaling and oxidative metabolism. Furthermore, protein expression of adipose triglyceride lipase (ATGL) (Ptime*group = 0.195), hormone-sensitive lipase (HSL) (Ptime*group = 0.458), HSL-ser660 phosphorylation (Ptime*group = 0.340), NP receptor-A (NPRA) (Ptime*group = 0.829) and OXPHOS complexes (Ptime*group = 0.964) remained unchanged. In conclusion, sacubitril/valsartan treatment for 8 weeks did not alter the abdominal subcutaneous AT transcriptome and expression of proteins involved in lipolysis, NP signaling and oxidative metabolism in obese hypertensive patients.
Subject(s)
Adipose Tissue/drug effects , Aminobutyrates/therapeutic use , Angiotensin Receptor Antagonists/therapeutic use , Hypertension/drug therapy , Neprilysin/antagonists & inhibitors , Obesity/metabolism , Proteins/metabolism , Tetrazoles/therapeutic use , Transcriptome , Adipose Tissue/metabolism , Adult , Aminobutyrates/pharmacology , Amlodipine/pharmacology , Angiotensin Receptor Antagonists/pharmacology , Biphenyl Compounds , Double-Blind Method , Drug Combinations , Female , Humans , Hypertension/complications , Hypertension/metabolism , Male , Middle Aged , Obesity/complications , Subcutaneous Fat/metabolism , Tetrazoles/pharmacology , ValsartanABSTRACT
Natriuretic peptide (NP) deficiency and sustained renin-angiotensin system activation are associated with impaired oxidative metabolism and predispose to type-2 diabetes. We hypothesized that sacubitril/valsartan (LCZ696), which augments NP through neprilysin inhibition while blocking angiotensin II type-1 (AT1 )-receptors, improves insulin sensitivity, lipid mobilization, and oxidation. After 8 weeks of treatment of obese patients with hypertension, sacubitril/valsartan 400 mg q.d., but not amlodipine 10 mg q.d., was associated with a significant increase from baseline in the insulin sensitivity index (hyperinsulinemic-euglycemic clamp), and tended to be higher in patients treated with sacubitril/valsartan compared to amlodipine. Abdominal adipose tissue interstitial glycerol concentrations increased with sacubitril/valsartan, but decreased with amlodipine. Whole-body lipolysis and substrate oxidation did not change with either treatment. Results confirm that sacubitril/valsartan treatment leads to a metabolic benefit in the study population and supports the relevance of neprilysin inhibition along with AT1 -receptor blockade in the regulation of human glucose and lipid metabolism.
Subject(s)
Aminobutyrates/pharmacology , Antihypertensive Agents/pharmacology , Insulin Resistance/physiology , Neprilysin/antagonists & inhibitors , Obesity/metabolism , Tetrazoles/pharmacology , Adipose Tissue/drug effects , Adult , Aminobutyrates/therapeutic use , Amlodipine/pharmacology , Angiotensin II Type 1 Receptor Blockers/metabolism , Biphenyl Compounds , Drug Combinations , Energy Metabolism/drug effects , Female , Glycerol/analysis , Humans , Hypertension/drug therapy , Lipid Metabolism/drug effects , Male , Middle Aged , Natriuretic Peptides/genetics , Natriuretic Peptides/metabolism , Renin-Angiotensin System/drug effects , Renin-Angiotensin System/physiology , Tetrazoles/therapeutic use , ValsartanABSTRACT
Disturbances in fatty acid metabolism in adipose tissue, liver, skeletal muscle, gut and pancreas play an important role in the development of insulin resistance, impaired glucose metabolism and type 2 diabetes mellitus. Alterations in diet composition may contribute to prevent and/or reverse these disturbances through modulation of fatty acid metabolism. Besides an increased fat mass, adipose tissue dysfunction, characterized by an altered capacity to store lipids and an altered secretion of adipokines, may result in lipid overflow, systemic inflammation and excessive lipid accumulation in non-adipose tissues like liver, skeletal muscle and the pancreas. These impairments together promote the development of impaired glucose metabolism, insulin resistance and type 2 diabetes mellitus. Furthermore, intrinsic functional impairments in either of these organs may contribute to lipotoxicity and insulin resistance. The present review provides an overview of fatty acid metabolism-related pathways in adipose tissue, liver, skeletal muscle, pancreas and gut, which can be targeted by diet or food components, thereby improving glucose metabolism.